Business Context and Reporting Period
Company: Generate Biomedicines, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 25, 2026
Event: Regulation FD Disclosure regarding the inadvertent early release of clinical trial data.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a disclosure of a specific corporate event rather than a financial report.
Material Changes and Event Details
On August 25, 2026, draft copies of three clinical trial posters intended for the European Respiratory Society Congress 2026 (ERS) were inadvertently made publicly available on the ERS website prior to the scheduled embargo expiration (September 7, 2026). The Company has attached the final versions of these posters as Exhibit 99.1 to ensure accurate information is available.
Disclosed Clinical Data Topics:
- GB-0895 (Asthma): Demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months.
- SOLAIRIA-1 & SOLAIRIA-2: Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895 in severe uncontrolled asthma.
- GB-0895 (COPD): Demonstrates potent and sustained pharmacological activity in adults with Chronic Obstructive Pulmonary Disease (COPD).
Guidance, Outlook, and Risks
Management Commentary: The Company issued this report as a precautionary measure to provide the final posters containing the information originally furnished to ERS.
Legal Status: The information provided under Item 7.01 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act. It is not subject to the liabilities of that section and shall not be deemed incorporated by reference in any other filing unless expressly stated.
Investor Verification Checklist
- Verify the specific data points and statistical significance within the attached Exhibit 99.1 posters.
- Confirm the timeline for the official presentation of these results at the ERS Congress (September 5-9, 2026).
- Assess the potential impact of the GB-0895 dosing frequency (every 6 months) on the competitive landscape for asthma and COPD treatments.
- Review subsequent press releases or 10-Q/10-K filings for any updated financial guidance related to these clinical milestones.